Lisa M. Pollack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa M. Pollack has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Feijun Luo
Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
14 shared publications - Jun Soo Lee
Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
14 shared publications - Sandra L. Jackson
Centers for Disease Control and Prevention
12 shared publications - Nicole Leigh Therrien
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
8 shared publications - Donglan Zhang
Division of Health Services Research, Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY, USA
5 shared publications - Ashutosh Kumar
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA (A.K., N.L.T., J.I.O., J.S.L., H.K.W., S.L.J.).
4 shared publications
Latest Publications
- Open Access
- 3 December 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (6) , 108212
Clinic Visit Timing, Prescribing Patterns, and Antihypertensive Medication Adherence: Evidence From Linked U.S. Electronic Health Records and Pharmacy Data
- 3 December 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (6) , 108212
Open AccessClinic Visit Timing, Prescribing Patterns, and Antihypertensive Medication Adherence: Evidence From Linked U.S. Electronic Health Records and Pharmacy Data
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (12) , e012067
Cardiac Rehabilitation Trends Among Commercially Insured Adults in the United States, 2017–2023
BACKGROUND: Cardiac rehabilitation (CR) reduces morbidity and mortality among individuals with heart disease. Although the COVID-19 pandemic disrupted health services, its impact on CR participation remains poorly understood—especially among commercially insured populations, for whom CR utilization trends are poorly documented. METHODS: This cross-sectional time series study of enrollees aged 18 to 64 years with ≥1 CR-qualifying event (acute myocardial infarction, coronary artery bypass graft, heart valve repair/replacement, percutaneous coronary intervention, or heart/heart-lung transplant) during 2017 to 2022, with follow-up through 2023, used MarketScan commercial claims data. Adjusted analyses used Poisson log-linear models with robust standard errors to examine trends in enrollment and completion (≥36 sessions), and generalized linear models with negative binomial distribution and log-link function to examine trends in days to enrollment and number of sessions. RESULTS: The sample included 143 870 unique individuals aged 18 to 64 years with a CR-qualifying event. Of the sample, the mean age was 53.9 (SD, 8.1), and 70% were men. On average, from 2017 to 2023, enrollment was 24.2%, days to enrollment were 46.3 (SD, 51.4 days), the number of sessions was 13.9 (SD, 12.8), and completion was 9.6%. Compared with year 2017, 2020 was associated with a 12% lower prevalence of enrollment (adjusted prevalence ratio, 0.88 [95% CI, 0.85–0.90]), 6-day longer time to enrollment on average (adjusted difference, 6.04 [95% CI, 4.36–7.72]), 1.2 fewer sessions on average (adjusted difference, −1.24 [95% CI, −1.72 to −0.75]), and 13% lower prevalence of completion (prevalence ratio, 0.87 [95% CI, 0.78–0.97]). All metrics rebounded to prepandemic levels, except days to enrollment (4 days longer in 2022 versus 2017; adjusted difference, 3.78 [95% CI, 2.22–5.34]). CONCLUSIONS: Among commercially insured adults <65 years, only one-quarter of eligible individuals participated in CR. CR metrics worsened during the COVID-19 pandemic in 2020, but most rebounded to prepandemic levels. These findings highlight an opportunity for health systems and public health initiatives to support broader CR uptake.
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (12) , e012067
Open AccessCardiac Rehabilitation Trends Among Commercially Insured Adults in the United States, 2017–2023
BACKGROUND: Cardiac rehabilitation (CR) reduces morbidity and mortality among individuals with heart disease. Although the COVID-19 pandemic disrupted health services, its impact on CR participation remains poorly understood—especially among commercially insured populations, for whom CR utilization trends are poorly documented. METHODS: This cross-sectional time series study of enrollees aged 18 to 64 years with ≥1 CR-qualifying event (acute myocardial infarction, coronary artery bypass graft, heart valve repair/replacement, percutaneous coronary intervention, or heart/heart-lung transplant) during 2017 to 2022, with follow-up through 2023, used MarketScan commercial claims data. Adjusted analyses used Poisson log-linear models with robust standard errors to examine trends in enrollment and completion (≥36 sessions), and generalized linear models with negative binomial distribution and log-link function to examine trends in days to enrollment and number of sessions. RESULTS: The sample included 143 870 unique individuals aged 18 to 64 years with a CR-qualifying event. Of the sample, the mean age was 53.9 (SD, 8.1), and 70% were men. On average, from 2017 to 2023, enrollment was 24.2%, days to enrollment were 46.3 (SD, 51.4 days), the number of sessions was 13.9 (SD, 12.8), and completion was 9.6%. Compared with year 2017, 2020 was associated with a 12% lower prevalence of enrollment (adjusted prevalence ratio, 0.88 [95% CI, 0.85–0.90]), 6-day longer time to enrollment on average (adjusted difference, 6.04 [95% CI, 4.36–7.72]), 1.2 fewer sessions on average (adjusted difference, −1.24 [95% CI, −1.72 to −0.75]), and 13% lower prevalence of completion (prevalence ratio, 0.87 [95% CI, 0.78–0.97]). All metrics rebounded to prepandemic levels, except days to enrollment (4 days longer in 2022 versus 2017; adjusted difference, 3.78 [95% CI, 2.22–5.34]). CONCLUSIONS: Among commercially insured adults <65 years, only one-quarter of eligible individuals participated in CR. CR metrics worsened during the COVID-19 pandemic in 2020, but most rebounded to prepandemic levels. These findings highlight an opportunity for health systems and public health initiatives to support broader CR uptake.
- 29 September 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (10) , qxaf190
New York state's paid family leave improved postpartum health care among women with hypertensive disorders in pregnancy
Introduction: Hypertensive disorders in pregnancy, including chronic and pregnancy-induced hypertension, pose significant risks to maternal health. This study evaluated the association of New York State (NYS)'s Paid Family Leave (PFL) law, implemented in 2018, with postpartum healthcare utilization among women with hypertensive disorders in pregnancy. Methods: Using commercial claims data (2017-2022) for 312 470 employed women aged 15-45 years with live births, we assessed postpartum outpatient visits, hospital admissions, and medication adherence. Results: The PFL law was associated with a 3.7%-point increase in outpatient visits within 7 days postpartum for women with chronic hypertension (from 25.9% to 29.6% in NYS, P < 0.001) and an 8.6%-point increase for women with pregnancy-induced hypertension (from 26.3% to 35.0%) in NYS, P < 0.001). The PFL law was associated with a 1.5%-point reduction in inpatient admissions for women with chronic hypertension (from 3.6% to 2.1% in NYS, P < 0.001), and a 7.1%-point improvement in antihypertensive medication adherence for women with chronic hypertension (from 26.6% to 33.8% in NYS, P < 0.001). Conclusion: Study findings suggest that PFL laws may enhance postpartum hypertension management, providing useful insights for policymakers aiming to improve maternal health outcomes through workplace policies.
- 29 September 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (10) , qxaf190
New York state's paid family leave improved postpartum health care among women with hypertensive disorders in pregnancy
Introduction: Hypertensive disorders in pregnancy, including chronic and pregnancy-induced hypertension, pose significant risks to maternal health. This study evaluated the association of New York State (NYS)'s Paid Family Leave (PFL) law, implemented in 2018, with postpartum healthcare utilization among women with hypertensive disorders in pregnancy. Methods: Using commercial claims data (2017-2022) for 312 470 employed women aged 15-45 years with live births, we assessed postpartum outpatient visits, hospital admissions, and medication adherence. Results: The PFL law was associated with a 3.7%-point increase in outpatient visits within 7 days postpartum for women with chronic hypertension (from 25.9% to 29.6% in NYS, P < 0.001) and an 8.6%-point increase for women with pregnancy-induced hypertension (from 26.3% to 35.0%) in NYS, P < 0.001). The PFL law was associated with a 1.5%-point reduction in inpatient admissions for women with chronic hypertension (from 3.6% to 2.1% in NYS, P < 0.001), and a 7.1%-point improvement in antihypertensive medication adherence for women with chronic hypertension (from 26.6% to 33.8% in NYS, P < 0.001). Conclusion: Study findings suggest that PFL laws may enhance postpartum hypertension management, providing useful insights for policymakers aiming to improve maternal health outcomes through workplace policies.
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e037811
Health Care Use and Expenditures Associated With Cardiac Rehabilitation Among Eligible Medicare Fee‐for‐Service Beneficiaries
Background: Cardiac rehabilitation (CR) can improve cardiovascular health. We identified whether CR participation was associated with fewer subsequent inpatient hospitalizations and emergency department visits and less Medicare and out‐of‐pocket expenditures, and whether outcomes varied by amount of participation. Methods: This retrospective study used Medicare fee‐for‐service claims data, including beneficiaries with a CR‐qualifying event in 2016. Participants attended ≥2 sessions of CR within 365 days of the event. Propensity score matching was used to identify CR‐eligible nonparticipants. Difference‐in‐differences analyses were used to compare differences in outcomes before (2014–2015) and after (2018–2019; 2‐year CR period=2016–2017) the CR period between participants and nonparticipants. Results: We identified 57 668 CR‐eligible beneficiaries after matching, with equal numbers of participants and nonparticipants. Nearly 65% of beneficiaries had a percutaneous coronary intervention, 33.5% had an acute myocardial infarction, 17.5% had a coronary artery bypass graft, and 16.8% had a heart valve repair/replacement. Compared with nonparticipants, participants had 47.6 fewer subsequent annual inpatient hospitalizations per 1000 beneficiaries (95% CI, −58.8 to −36.3) and $1005 lower subsequent annual Medicare expenditures per beneficiary (95% CI, −$1352 to −$659). Compared with no participation, medium participation (12–23 sessions), high participation (24–35 sessions), and CR completion (≥36 sessions) were associated with fewer inpatient hospitalizations and lower Medicare expenditures per year. Conclusions: CR was associated with fewer subsequent annual inpatient hospitalizations and lower subsequent annual Medicare expenditures. A higher amount of participation was associated with a further reduction in hospitalizations and expenditures. These findings can inform programs and policies that encourage CR participation.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e037811
Open AccessHealth Care Use and Expenditures Associated With Cardiac Rehabilitation Among Eligible Medicare Fee‐for‐Service Beneficiaries
Background: Cardiac rehabilitation (CR) can improve cardiovascular health. We identified whether CR participation was associated with fewer subsequent inpatient hospitalizations and emergency department visits and less Medicare and out‐of‐pocket expenditures, and whether outcomes varied by amount of participation. Methods: This retrospective study used Medicare fee‐for‐service claims data, including beneficiaries with a CR‐qualifying event in 2016. Participants attended ≥2 sessions of CR within 365 days of the event. Propensity score matching was used to identify CR‐eligible nonparticipants. Difference‐in‐differences analyses were used to compare differences in outcomes before (2014–2015) and after (2018–2019; 2‐year CR period=2016–2017) the CR period between participants and nonparticipants. Results: We identified 57 668 CR‐eligible beneficiaries after matching, with equal numbers of participants and nonparticipants. Nearly 65% of beneficiaries had a percutaneous coronary intervention, 33.5% had an acute myocardial infarction, 17.5% had a coronary artery bypass graft, and 16.8% had a heart valve repair/replacement. Compared with nonparticipants, participants had 47.6 fewer subsequent annual inpatient hospitalizations per 1000 beneficiaries (95% CI, −58.8 to −36.3) and $1005 lower subsequent annual Medicare expenditures per beneficiary (95% CI, −$1352 to −$659). Compared with no participation, medium participation (12–23 sessions), high participation (24–35 sessions), and CR completion (≥36 sessions) were associated with fewer inpatient hospitalizations and lower Medicare expenditures per year. Conclusions: CR was associated with fewer subsequent annual inpatient hospitalizations and lower subsequent annual Medicare expenditures. A higher amount of participation was associated with a further reduction in hospitalizations and expenditures. These findings can inform programs and policies that encourage CR participation.
- 13 December 2024
- Published by Elsevier in American Heart Journal
- Vol. 282, 58-69
Hospital-level variation in cardiac rehabilitation metrics
- 13 December 2024
- Published by Elsevier in American Heart Journal
- Vol. 282, 58-69
Hospital-level variation in cardiac rehabilitation metrics
- Open Access
Fixed-Dose Combination Use and Drug Adherence, Healthcare Utilization, and Costs
BACKGROUND: Combination-pill therapy using fixed-dose combination (FDC) antihypertensives has the potential to improve hypertension control and management. However, combination-pill therapy remains low. This study aims to assess 1) the association between combination-pill therapy and subsequent medication adherence, healthcare utilization, and costs and 2) the potential to mitigate racial and ethnic disparities in medication adherence, among Medicaid beneficiaries. METHODS: A retrospective cohort analysis was conducted using the 2017-2021 Merative TM MarketScan® Medicaid claims database. The study sample included adults aged 18-64 years with hypertension, continuously enrolled one year before and after a random index date of prescribed antihypertensives. Combination-pill therapy was compared with multi-pill therapy. The propensity-score overlap weighting method was used to balance characteristics between individuals using combination- and multi-pill therapy. Logistic models were used for medication adherence, linear models for medication possession ratios (MPRs), negative binomial models for healthcare utilization, and generalized linear models for healthcare costs. RESULTS: Compared with multi-pill therapy, combination-pill therapy was associated with improved medication adherence (3.17 in MPR, 95% CI: 2.79 - 3.55), fewer hypertension-related emergency department visits (220 per 1,000 individuals, 95% CI: -235 – -204), fewer hospitalizations (153 per 1,000 individuals, 95% CI: -160 – -146), and lower medical costs ($2,862 per person, 95% CI: -$3,035 – -$2,689). However, disparities in medication adherence between non-Hispanic White and non-Hispanic Black adults existed for both FDC and multi-pill therapy. CONCLUSIONS: Combination-pill therapy could improve hypertension management and save costs for the Medicaid program and beneficiaries. These findings may inform policies on FDC antihypertensive coverage and programs. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
Open AccessFixed-Dose Combination Use and Drug Adherence, Healthcare Utilization, and Costs
BACKGROUND: Combination-pill therapy using fixed-dose combination (FDC) antihypertensives has the potential to improve hypertension control and management. However, combination-pill therapy remains low. This study aims to assess 1) the association between combination-pill therapy and subsequent medication adherence, healthcare utilization, and costs and 2) the potential to mitigate racial and ethnic disparities in medication adherence, among Medicaid beneficiaries. METHODS: A retrospective cohort analysis was conducted using the 2017-2021 Merative TM MarketScan® Medicaid claims database. The study sample included adults aged 18-64 years with hypertension, continuously enrolled one year before and after a random index date of prescribed antihypertensives. Combination-pill therapy was compared with multi-pill therapy. The propensity-score overlap weighting method was used to balance characteristics between individuals using combination- and multi-pill therapy. Logistic models were used for medication adherence, linear models for medication possession ratios (MPRs), negative binomial models for healthcare utilization, and generalized linear models for healthcare costs. RESULTS: Compared with multi-pill therapy, combination-pill therapy was associated with improved medication adherence (3.17 in MPR, 95% CI: 2.79 - 3.55), fewer hypertension-related emergency department visits (220 per 1,000 individuals, 95% CI: -235 – -204), fewer hospitalizations (153 per 1,000 individuals, 95% CI: -160 – -146), and lower medical costs ($2,862 per person, 95% CI: -$3,035 – -$2,689). However, disparities in medication adherence between non-Hispanic White and non-Hispanic Black adults existed for both FDC and multi-pill therapy. CONCLUSIONS: Combination-pill therapy could improve hypertension management and save costs for the Medicaid program and beneficiaries. These findings may inform policies on FDC antihypertensive coverage and programs. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
- Open Access
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e037357
Antihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension
Background: Hypertension affects nearly half of US adults yet remains inadequately controlled in over three‐quarters of these cases. This study aimed to assess the association between adherence to antihypertensive medications and total medical costs, health care use, and productivity‐related outcomes. Methods and Results: We conducted cross‐sectional analyses using MarketScan databases, which included individuals aged 18 to 64 years with noncapitated health insurance plans in 2019. Adherence was defined as ≥80% medication possession ratio for prescribed antihypertensive medications. We used a generalized linear model to estimate total medical costs, a negative binomial model to estimate health care use (emergency department visits and inpatient admissions), an exponential hurdle model to estimate productivity‐related outcomes (number of sick absences, short‐term disability, long‐term disability), and a 2‐part model to estimate productivity‐related costs in 2019 US dollars. All models were adjusted for age, sex, urbanicity, census region, and comorbidities. We reported average marginal effects for outcomes related to antihypertensive medication adherence. Among 379 503 individuals with hypertension in 2019, 54.4% adhered to antihypertensives. Per person, antihypertensive medication adherence was associated with $1441 lower total medical costs, $11 lower sick absence costs, $291 lower short‐term disability costs, and $69 lower long‐term disability costs. Per 1000 individuals, medication adherence was associated with lower health care use, including 200 fewer emergency department visits and 90 fewer inpatient admissions, and productivity‐related outcomes, including 20 fewer sick absence days and 442 fewer short‐term disability days. Conclusions: Adherence to antihypertensives was consistently associated with lower total medical costs, reduced health care use, and improved productivity‐related outcomes.
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e037357
Open AccessAntihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension
Background: Hypertension affects nearly half of US adults yet remains inadequately controlled in over three‐quarters of these cases. This study aimed to assess the association between adherence to antihypertensive medications and total medical costs, health care use, and productivity‐related outcomes. Methods and Results: We conducted cross‐sectional analyses using MarketScan databases, which included individuals aged 18 to 64 years with noncapitated health insurance plans in 2019. Adherence was defined as ≥80% medication possession ratio for prescribed antihypertensive medications. We used a generalized linear model to estimate total medical costs, a negative binomial model to estimate health care use (emergency department visits and inpatient admissions), an exponential hurdle model to estimate productivity‐related outcomes (number of sick absences, short‐term disability, long‐term disability), and a 2‐part model to estimate productivity‐related costs in 2019 US dollars. All models were adjusted for age, sex, urbanicity, census region, and comorbidities. We reported average marginal effects for outcomes related to antihypertensive medication adherence. Among 379 503 individuals with hypertension in 2019, 54.4% adhered to antihypertensives. Per person, antihypertensive medication adherence was associated with $1441 lower total medical costs, $11 lower sick absence costs, $291 lower short‐term disability costs, and $69 lower long‐term disability costs. Per 1000 individuals, medication adherence was associated with lower health care use, including 200 fewer emergency department visits and 90 fewer inpatient admissions, and productivity‐related outcomes, including 20 fewer sick absence days and 442 fewer short‐term disability days. Conclusions: Adherence to antihypertensives was consistently associated with lower total medical costs, reduced health care use, and improved productivity‐related outcomes.
- 1 November 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (11) , 2318-2328
Hypertension-Associated Expenditures Among Privately Insured US Adults in 2021
BACKGROUND: There are no recent estimates for hypertension-associated medical expenditures. This study aims to estimate hypertension-associated incremental medical expenditures among privately insured US adults. METHODS: We conducted a retrospective cohort study using IQVIA’s Ambulatory Electronic Medical Records-US data set linked with PharMetrics Plus claims data. Among privately insured adults aged 18 to 64 years, hypertension was identified as having ≥1 diagnosis code or ≥2 blood pressure measurements of ≥140/90 mm Hg, or ≥1 antihypertensive medication in 2021. Annual total expenditures (in 2021 $US) were estimated using a generalized linear model with gamma distribution and log-link function adjusting for demographic characteristics and cooccurring conditions. Out-of-pocket expenditures were estimated using a 2-part model that included logistic and generalized linear model regression. Overlap propensity score weights from logistic regression were used to obtain a balanced sample on hypertension status. RESULTS: Among the 393 018 adults, 156 556 (40%) were identified with hypertension. Compared with individuals without hypertension, those with hypertension had $2926 (95% CI, $2681–$3170) higher total expenditures and $328 (95% CI, $300–$355) higher out-of-pocket expenditures. Adults with hypertension had higher total inpatient ($3272 [95% CI, $1458–$5086]) and outpatient ($2189 [95% CI, $2009–$2369]) expenditures when compared with those without hypertension. Hypertension-associated incremental total expenditures were higher for women ($3242 [95% CI, $2915–$3569]) than for men ($2521 [95% CI, $2139–$2904]). CONCLUSIONS: Among privately insured US adults, hypertension was associated with higher medical expenditures, including higher inpatient and out-of-pocket expenditures. These findings may help assess the economic value of interventions effective in preventing hypertension.
- 1 November 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (11) , 2318-2328
Hypertension-Associated Expenditures Among Privately Insured US Adults in 2021
BACKGROUND: There are no recent estimates for hypertension-associated medical expenditures. This study aims to estimate hypertension-associated incremental medical expenditures among privately insured US adults. METHODS: We conducted a retrospective cohort study using IQVIA’s Ambulatory Electronic Medical Records-US data set linked with PharMetrics Plus claims data. Among privately insured adults aged 18 to 64 years, hypertension was identified as having ≥1 diagnosis code or ≥2 blood pressure measurements of ≥140/90 mm Hg, or ≥1 antihypertensive medication in 2021. Annual total expenditures (in 2021 $US) were estimated using a generalized linear model with gamma distribution and log-link function adjusting for demographic characteristics and cooccurring conditions. Out-of-pocket expenditures were estimated using a 2-part model that included logistic and generalized linear model regression. Overlap propensity score weights from logistic regression were used to obtain a balanced sample on hypertension status. RESULTS: Among the 393 018 adults, 156 556 (40%) were identified with hypertension. Compared with individuals without hypertension, those with hypertension had $2926 (95% CI, $2681–$3170) higher total expenditures and $328 (95% CI, $300–$355) higher out-of-pocket expenditures. Adults with hypertension had higher total inpatient ($3272 [95% CI, $1458–$5086]) and outpatient ($2189 [95% CI, $2009–$2369]) expenditures when compared with those without hypertension. Hypertension-associated incremental total expenditures were higher for women ($3242 [95% CI, $2915–$3569]) than for men ($2521 [95% CI, $2139–$2904]). CONCLUSIONS: Among privately insured US adults, hypertension was associated with higher medical expenditures, including higher inpatient and out-of-pocket expenditures. These findings may help assess the economic value of interventions effective in preventing hypertension.
- Open Access
- 6 October 2024
- Published by Elsevier in AJPM Focus
- Vol. 4 (1) , 100285
Costs and Healthcare Utilization of Heart Disease by COVID-19 Diagnosis and Race and Ethnicity
- 6 October 2024
- Published by Elsevier in AJPM Focus
- Vol. 4 (1) , 100285
Open AccessCosts and Healthcare Utilization of Heart Disease by COVID-19 Diagnosis and Race and Ethnicity
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (8) , e010739
Impact of State Telehealth Parity Laws for Private Payers on Hypertension Medication Adherence Before and During the COVID-19 Pandemic
BACKGROUND: Telehealth has emerged as an effective tool for managing common chronic conditions such as hypertension, especially during the COVID-19 pandemic. However, the impact of state telehealth payment and coverage parity laws on hypertension medication adherence remains uncertain. METHODS: Data from the 2016 to 2021 Merative MarketScan Commercial Claims and Encounters Database were used to construct the study cohort, which included nonpregnant individuals aged 25 to 64 years with hypertension. We coded telehealth parity laws related to hypertension management in all 50 US states and the District of Columbia, distinguishing between payment and coverage parity laws. The primary outcomes were measures of antihypertension medication adherence: the average medication possession ratio; medication adherence (medication possession ratio ≥80%); and average number of days of drug supply. We used a generalized difference-in-differences design to examine the impact of these laws. RESULTS: Among 353 220 individuals (mean [SD] age, 49.5 (7.1) years; female, 45.55%), states with payment parity laws were significantly linked to increased average medication possession ratio by 0.43 percentage point (95% CI, 0.07–0.79), and an increase of 0.46 percentage point (95% CI, 0.06–0.92) in the probability of medication adherence. Payment parity laws also led to an average increase of 2.14 days (95% CI, 0.11–4.17) in prescription supply, after controlling for state-fixed effects, year-fixed effects, individual sociodemographic characteristics and state time-varying covariates including unemployment rates, gross domestic product per capita, and poverty rates. In contrast, coverage parity laws were associated with a 2.13-day increase (95% CI, 0.19–4.07) in days of prescription supply but did not significantly increase the average medication possession ratio or probability of medication adherence. CONCLUSIONS: State telehealth payment parity laws were significantly associated with greater medication adherence, whereas coverage parity laws were not. With the increasing adoption of telehealth parity laws across states, these findings may support policymakers in understanding potential implications on management of hypertension.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (8) , e010739
Impact of State Telehealth Parity Laws for Private Payers on Hypertension Medication Adherence Before and During the COVID-19 Pandemic
BACKGROUND: Telehealth has emerged as an effective tool for managing common chronic conditions such as hypertension, especially during the COVID-19 pandemic. However, the impact of state telehealth payment and coverage parity laws on hypertension medication adherence remains uncertain. METHODS: Data from the 2016 to 2021 Merative MarketScan Commercial Claims and Encounters Database were used to construct the study cohort, which included nonpregnant individuals aged 25 to 64 years with hypertension. We coded telehealth parity laws related to hypertension management in all 50 US states and the District of Columbia, distinguishing between payment and coverage parity laws. The primary outcomes were measures of antihypertension medication adherence: the average medication possession ratio; medication adherence (medication possession ratio ≥80%); and average number of days of drug supply. We used a generalized difference-in-differences design to examine the impact of these laws. RESULTS: Among 353 220 individuals (mean [SD] age, 49.5 (7.1) years; female, 45.55%), states with payment parity laws were significantly linked to increased average medication possession ratio by 0.43 percentage point (95% CI, 0.07–0.79), and an increase of 0.46 percentage point (95% CI, 0.06–0.92) in the probability of medication adherence. Payment parity laws also led to an average increase of 2.14 days (95% CI, 0.11–4.17) in prescription supply, after controlling for state-fixed effects, year-fixed effects, individual sociodemographic characteristics and state time-varying covariates including unemployment rates, gross domestic product per capita, and poverty rates. In contrast, coverage parity laws were associated with a 2.13-day increase (95% CI, 0.19–4.07) in days of prescription supply but did not significantly increase the average medication possession ratio or probability of medication adherence. CONCLUSIONS: State telehealth payment parity laws were significantly associated with greater medication adherence, whereas coverage parity laws were not. With the increasing adoption of telehealth parity laws across states, these findings may support policymakers in understanding potential implications on management of hypertension.